September 20, 2019
JCR Pharmaceuticals said on September 19 that it has withdrawn its application in Japan for the label expansion of its human mesenchymal stem cell therapy Temcell for the treatment of epidermolysis bullosa (EB) in order to demonstrate its efficacy “with...read more